A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation

Table 1 Select Immuno-Oncology Therapies Discussed at NIBIT Think Tank Meetings 2018–2020

Key Therapies up to 2019	Ref	Key Recent Developments 2019/2020	Ref
NSCLC
Pembrolizumab for > 50% PDL1	[4]	Cemiplimab for > 50% PDL1	[25]
Atezolizumab for > 50% PDL1	[7]
Pembrolizumab +chemotherapy for < 50% PDL1	[5, 6]	Nivolumab/Ipilimumab + 2 cycles chemotherapy	[20]
		Atezolizumab + tiragolumab	[30]
		Pembrolizumab + ipilimumab (No Improvement in > 50% PD-L1⁺ Patients)	[29]
Cutaneous Melanoma
• BRAF/MEK • Nivolumab/Ipilimumab • Pembrolizumab	[31]	Pembrolizumab + lenvatinib	[32]
Ipilimumab +Fotemustine in brain metastasis	[33]	Atezolizumab was added after 1 cycle of vemurafenib and cobimetinib	[34]
Ipilimumab + guadecitabine	[35]
Mesothelioma
Pemetrexed/Platinum	[36]	Tremelimumab + durvalumab	[37,38,39,40,41,42,43,44,45]
		Nivolumab + ipilimumab	[46]
		Nivolumab	[47]